Comparative neuropharmacology of three psychostimulant cathinone derivatives: Butylone, mephedrone and methylone

British Journal of Pharmacology

Volumn 167, Issue 2, 2012, Pages 407-420

  Lõpez Arnau, Raul ^a   Martínez Clemente, Jose ^a   Pubill, David ^a   Escubedo, Elena ^a   Camarasa, Jorge ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

butylone; dopamine; locomotor activity; mephedrone; methylone; serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; BUTYLONE; DOPAMINE; DOPAMINE TRANSPORTER; FENCLONINE; HALOPERIDOL; KETANSERIN; METHAMPHETAMINE; METHYLONE; PSYCHOSTIMULANT AGENT; SB 216641; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN SYNAPTOSOME; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; DRUG RECEPTOR BINDING; LOCOMOTION; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BRAIN; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; KETANSERIN; MALE; METHAMPHETAMINE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN ANTAGONISTS; SYNAPTOSOMES;

EID: 84865424242     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01998.x     Document Type: Article

References (47)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP, (2004). 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 20: 3073-3084. (Pubitemid 40007302)
3. Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB, (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159-163.
4. Bossong MG, Van Dijk JP, Niesink RJ, (2005). Methylone and mCPP, two new drugs of abuse? Addict Biol 10: 321-323. (Pubitemid 41759265)
5. Brunt TM, Poortman A, Niesink RJ, Van den Brink W, (2011). Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25: 1543-1547.
6. Camarasa J, García-Ratés S, Pubill D, Escubedo E, (2009). The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice. Behav Pharmacol 20: 623-630.
7. Chad RM, Copeland CR, (2010). Characterization of three methcathinone analogs: 4-methylmethcathinone, methylone and bk-MBDB. Microgram J 7: 42-49.
8. Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E, (2008a). Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochem Int 52: 401-410.
9. Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E, (2008b). Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 54: 1254-1263.
10. Clark MS, Sexton TJ, McClain M, Root D, Kohen R, Neumaier JF, (2002). Overexpression of 5-HT1B receptor in dorsal raphe nucleus using herpes simplex virus gene transfer increases anxiety behaviour after inescapable stress. J Neurosci 22: 4550-4562. (Pubitemid 37465671)
11. Cozzi NV, Sievert MK, Shulgin AT, Jacobill P, Rhuolo AE, (1999). Inhibition of plasma membrane monoamine transporters by betaketoamphetamines. Eur J Pharmacol 381: 63-69. (Pubitemid 29488590)
12. Drug Enforcement Administration, Department of Justice (2011). Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist 76: 65371-65375.
13. Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C, et al,. (2011). In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') and hallucinogen users. Arch Gen Psychiatr 68: 562-576.
14. Escubedo E, Chipana C, Pérez-Sanchez M, Camarasa J, Pubill D, (2005). Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther 315: 658-667. (Pubitemid 41500731)
15. Fischer JF, Cho AK, (1979). Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208: 203-209. (Pubitemid 9191709)
16. Fleckenstein AE, Voltz TJ, Riddle EL, Gibb JW, Hanson GR, (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681-698.
17. Foster JD, Cervinski MA, Gorentla BK, Vaughan RA, (2006). Regulation of the dopamine transporter by phosphorylation. Handb Exp Pharmacol 175: 197-214.
18. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, et al,. (2011). 4-methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530-536.
19. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, et al,. (2002). Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300: 1093-1100. (Pubitemid 34165017)
20. Hrometz SL, Brown AW, Nichols DE, Sprague JE, (2004). 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci Lett 367: 56-59. (Pubitemid 39078784)
21. Izawa J, Yamanashi K, Asakura T, Misu Y, Goshima Y, (2006). Differential effects of methamphetamine and cocaine on behaviour and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats. Eur J Pharmacol 549: 84-90. (Pubitemid 44441268)
22. Jayanthi LD, Samuvel DJ, Blakely RD, Ramamoorthy S, (2005). Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol Pharmacol 67: 2077-2087. (Pubitemid 41007790)
23. Jones DC, Lau SS, Monks TJ, (2004). Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther 311: 298-306. (Pubitemid 39287809)
24. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, et al,. (2011). Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 1949-1958.
25. Kot M, Daniel WA, (2011). Cytochrome P450 is regulated by noradrenergic and serotonergic systems. Pharmacol Res 64: 371-380.
26. Levi G, Raiteri M, (1993). Carrier-mediated release of neurotransmitters. Trends Neurosci 16: 415-419. (Pubitemid 23283403)
27. Leviel V, (2001). The reverse transport of DA, what physiological significance? Neurochem Int 38: 83-106. (Pubitemid 32014380)
28. Ljungberg T, Ungerstedt U, (1985). A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23: 479-485. (Pubitemid 16256920)
29. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J, (2012). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22: 231-236.
30. McCreary AC, Bankson MG, Cunningham KA, (1999). Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine (1A) and 5-hydroxytryptamine(1B/ 1D) receptors. J Pharmacol Exp Ther 290: 965-973. (Pubitemid 29400232)
31. McElrath K, O'Neill C, (2011). Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22: 120-127.
32. McGrath JC, Drummond GB, McLachlan E, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Measham F, Moore K, Newcombe R, Welch Z, (2010). Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 10: 14-21.
34. Meng H, Cao J, Kang J, Ying X, Ji J, Reynolds W, et al,. (2012). Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol Lett 208: 62-68.
35. Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS, (2012). Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17: 409-422.
36. Nagai F, Nonaka R, Satoh K, Kamimura SHK, (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559: 132-137. (Pubitemid 46295399)
37. Pubill D, Chipana C, Camins A, Pallas M, Camarasa J, Escubedo E, (2005). Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol 204: 57-68. (Pubitemid 40387567)
38. Ramamoorthy S, Shippenberg TS, Jayanthi LD, (2011). Regulation of monoamine transporters: role of transporter phosphorylation. Pharmacol Ther 129: 220-238.
39. Regan L, Mitchelson M, MacDonald C, (2011). Mephedrone toxicity in a Scottish emergency department. Emerg Med J 28: 1055-1058.
40. Rudnick G, Wall SC, (1992). The molecular mechanism of 'ecstasy'[3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89: 1817-1821.
41. Schifano F, Albanese A, Fergus S, Stair JL, DeLuca P, Corazza O, et al,. (2011). Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 214: 593-602.
42. Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnik G, (1993). Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 44: 1227-1231. (Pubitemid 24008607)
43. Vardakou I, Pistos C, Spiliopoulou CH, (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191-195.
44. Winstock A, Mitcheson L, Masden J, (2010). Mephedrone: still available and twice the price. Lancet 376: 1537.
45. Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J, (2011). Mephedrone: use, subjective effects and health risks. Addiction 106: 1991-1996.
46. Wood D, Dargan P, (2010). 'Mephedrone' (4-methylmethcathinone): what is it, how commonly is it used and what are the risks associated with its use? Pharmacol Matters 3: 11-14.
47. Yamamoto BK, Nash JF, Gudelsky GA, (1995). Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273: 1063-1070.